Alirocumab in Patients on a Stable Dialysis Regimen
A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study
Sponsor: Baylor Research Institute
A PHASE3 clinical study on Atherosclerotic Disease and Hemodialysis, this trial is ongoing. The trial is conducted by Baylor Research Institute and has accumulated 9 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Sep 2019 — Mar 2020 [monthly]
Recruiting PHASE3
-
Nov 2018 — Sep 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor Research Institute
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .